SARS-CoV-2 spike ectodomain targets α7 nicotinic acetylcholine receptors DOI Creative Commons

Brittany C V O'Brien,

Lahra Weber,

Karsten Hueffer

et al.

Journal of Biological Chemistry, Journal Year: 2023, Volume and Issue: 299(5), P. 104707 - 104707

Published: April 13, 2023

Virus entry into animal cells is initiated by attachment to target macromolecules located on host cells. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike glycoprotein targets angiotensin converting enzyme gain cellular access. SARS-CoV-2 contains a neurotoxin-like region that has sequence similarities the rabies virus and HIV glycoproteins, as well snake neurotoxins, which interact with nicotinic acetylcholine receptor (nAChR) subtypes via this region. Using peptide of (SARS-CoV-2 [SCoV2P]), we identified area moderately inhibits α3β2, α3β4, α4β2 subtypes, while potentiating inhibiting α7 nAChRs. These nAChR are found in tissues including nose, lung, central nervous system, immune Importantly, SCoV2P potentiates ACh-induced responses an allosteric mechanism, nicotine enhancing these effects. Live-cell confocal microscopy was used confirm interacts nAChRs transfected neuronal-like N2a human embryonic kidney 293 ectodomain functionally subtype nanomolar potency. Our functional findings identify for glycoprotein, providing new aspect our understanding cell interactions, addition disease pathogenesis.

Language: Английский

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study DOI Creative Commons
Cristina Menni, Ana M. Valdes,

Lorenzo Polidori

et al.

The Lancet, Journal Year: 2022, Volume and Issue: 399(10335), P. 1618 - 1624

Published: April 1, 2022

The SARS-CoV-2 variant of concern, omicron, appears to be less severe than delta. We aim quantify the differences in symptom prevalence, risk hospital admission, and duration among vaccinated population.

Language: Английский

Citations

795
Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis DOI Open Access
Preeti Malik, Karan Patel, Cândida Pinto

et al.

Journal of Medical Virology, Journal Year: 2021, Volume and Issue: 94(1), P. 253 - 262

Published: Aug. 31, 2021

There is an established literature on the symptoms and complications of COVID-19 but after-effects are not well understood with few studies reporting persistent quality life. We aim to evaluate pooled prevalence poor life in post-acute syndrome (PCS) conducted meta-regression effects intensive care unit (ICU) admission extracted data from observational describing post-COVID-19 patients March 10, 2020, 2021, following PRISMA guidelines a consensus two independent reviewers. calculated 95% confidence interval (CI) created forest plots using random-effects models. A total 12 4828 PCS were included. found that amongst patients, (EQ-VAS) was (59%; CI: 42%-75%). Based individual factors EQ-5D-5L questionnaire, mobility (36, 10-67), personal (8, 1-21), usual (28, 2-65), pain/discomfort (42, 28-55), anxiety/depression (38, 19-58). The fatigue (64, 54-73), dyspnea (39.5, 20-60), anosmia (20, 15-24), arthralgia (24.3, 14-36), headache (21, 3-47), sleep disturbances (47, 7-89), mental health (14.5, 4-29). Meta-regression analysis showed significantly higher among ICU (p = 0.004) 0.0015). Our study concludes associated life, including fatigue, dyspnea, anosmia, disturbances, worse health. This suggests we need more research understand risk causing it eventually leading

Language: Английский

Citations

536
Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19 DOI Creative Commons
Rakhee K. Ramakrishnan, Tarek Kashour, Qutayba Hamid

et al.

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: June 30, 2021

More than one year since its emergence, corona virus disease 2019 (COVID-19) is still looming large with a paucity of treatment options. To add to this burden, sizeable subset patients who have recovered from acute COVID-19 infection reported lingering symptoms, leading significant disability and impairment their daily life activities. These are considered suffer what has been termed as “chronic” or “long” form post-acute sequelae COVID-19, experiencing syndrome long-haulers. Despite recovery infection, the persistence atypical chronic including extreme fatigue, shortness breath, joint pains, brain fogs, anxiety depression, that could last for months implies an underlying pathology persist beyond presentation disease. As opposed direct effects itself, immune response severe respiratory coronavirus 2 (SARS-CoV-2) believed be largely responsible appearance these lasting possibly through facilitating ongoing inflammatory process. In review, we hypothesize potential immunological mechanisms persistent prolonged effects, describe multi-organ long-term manifestations COVID-19.

Language: Английский

Citations

218
COVID-19-associated opportunistic infections: a snapshot on the current reports DOI Creative Commons
Amir Abdoli, Shahab Falahi, Azra Kenarkoohi

et al.

Clinical and Experimental Medicine, Journal Year: 2021, Volume and Issue: 22(3), P. 327 - 346

Published: Aug. 23, 2021

Language: Английский

Citations

132
Vitamin D supplementation for the treatment of COVID-19: a living systematic review DOI

Julia Kristin Stroehlein,

Julia Wallqvist,

Claire Iannizzi

et al.

Cochrane library, Journal Year: 2021, Volume and Issue: 2021(5)

Published: May 24, 2021

Language: Английский

Citations

108
Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank DOI Open Access
Eric Yuk Fai Wan, Sukriti Mathur, Ran Zhang

et al.

Cardiovascular Research, Journal Year: 2023, Volume and Issue: 119(8), P. 1718 - 1727

Published: Jan. 19, 2023

This study aims to evaluate the short- and long-term associations between COVID-19 development of cardiovascular disease (CVD) outcomes mortality in general population.A prospective cohort patients with infection 16 March 2020 30 November was identified from UK Biobank, followed for up 18 months, until 31 August 2021. Based on age (within 5 years) sex, each case randomly matched 10 participants without two cohorts-a contemporary a historical 2018 2018. The characteristics groups were further adjusted propensity score-based marginal mean weighting through stratification. To determine association CVD within 21 days diagnosis (acute phase) after this period (post-acute phase), Cox regression employed. In acute phase, (n = 7584) associated significantly higher short-term risk {hazard ratio (HR): 4.3 [95% confidence interval (CI): 2.6- 6.9]; HR: 5.0 (95% CI: 3.0-8.1)} all-cause [HR: 81.1 58.5-112.4); 67.5 49.9-91.1)] than 75 790) controls 774), respectively. Regarding post-acute 7139) persisted 1.4 1.2-1.8); 1.3 1.1- 1.6)] 4.3-5.8); 4.5 3.9-5.2) compared 71 296) 314), respectively.COVID-19 infection, including long-COVID, is increased risks mortality. Ongoing monitoring signs symptoms developing these complications post till at least year recovery may benefit infected patients, especially those severe disease.

Language: Английский

Citations

87
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication DOI Creative Commons
Qin Ning, Di Wu, Xiaojing Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Feb. 23, 2022

Abstract The coronavirus disease 2019 (COVID-19) is a highly transmissible caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) that poses major threat to global public health. Although COVID-19 primarily affects system, causing pneumonia and distress in cases, it can also result multiple extrapulmonary complications. pathogenesis of damage patients with probably multifactorial, involving both direct effects SARS-CoV-2 indirect mechanisms associated host inflammatory response. Recognition features complications has clinical implications for identifying progression designing therapeutic strategies. This review provides an overview from immunological pathophysiologic perspectives focuses on potential targets management COVID-19.

Language: Английский

Citations

72
Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-α) in COVID-19: Prognosis, Therapeutic and Management DOI Open Access
Zarina Mohd Zawawi,

Jeevanathan Kalyanasundram,

Rozainanee Mohd Zain

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(7), P. 6142 - 6142

Published: March 24, 2023

The coronavirus disease 2019 (COVID-19) became a worldwide concern at the beginning of 2020 and has affected millions. Several previous studies revealed impact imbalanced innate immune response on progression COVID-19 its outcomes. High levels proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) interleukins are produced readily by cells to fight Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infections. Nonetheless, cytokine-mediated inflammatory events also linked detrimental lung injury respiratory failure, which can result in deaths among patients. TNF-α is amongst early mediate responses enhance cell infiltration SARS-CoV-2 In COVID-19, TNF-α-mediated inflammation cause tissue damage gradually promotes fibrosis, later results pneumonia, pulmonary edema, acute distress syndrome. This review, therefore, aims deliberate immunomodulatory roles promoting relation with morbidity mortality. addition, this review proposes potential biomarker for prognosis severe related complications molecular target anti-TNF-α therapy.

Language: Английский

Citations

45
Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial DOI Creative Commons
Morteza Zarrabi, Mohammad Amin Shahrbaf, Masoumeh Nouri

et al.

Stem Cell Research & Therapy, Journal Year: 2023, Volume and Issue: 14(1)

Published: June 26, 2023

The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy their derivatives can be used to relieve inflammation these cases. In this study, we aimed evaluate the safety efficacy using mesenchymal stromal cells (MSCs) derived extracellular vesicles COVID-19 patients.

Language: Английский

Citations

43
Covid-19 Infection in India: A Comparative Analysis of the Second Wave with the First Wave DOI Creative Commons
Arnab Sarkar,

Alok K. Chakrabarti,

Shanta Dutta

et al.

Pathogens, Journal Year: 2021, Volume and Issue: 10(9), P. 1222 - 1222

Published: Sept. 21, 2021

Coronavirus disease 2019 (COVID-19) is considered as the most dreaded that has spread all over world in recent past. Despite its outbreak December 2019–January 2020, a few continents and countries such India started to experience significant number of COVID-19-positive cases from March 2020. GISAID clade variation analysis period 2020–February 2021 (period I) 2021–first week April II) showed rapid SARS-CoV-2 time. Studying relationship patient age or gender with viral clades these two periods revealed population under 10 years was least affected, whereas 11–60-year-old irrespective ethnicity. In first wave, registered quite low cases/million people, but scenario unexpectedly changed second when even 400,000 confirmed cases/day were reported. Lineage emergence new variants, i.e., B.1.617.1 B.1.617.2, during April–May 2021, which might be one key reasons for sudden upsurge cases/day. Furthermore, variants contributed shift infection by G 46% II 82.34% end May 2021. Along management factors viz., lockdown vaccination also accountable controlling COVID-19 throughout country. Collectively, comparative wave would suggest policymakers way prepare better recurrence severity other countries.

Language: Английский

Citations

89